Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma
- PMID: 3481362
- DOI: 10.1007/BF00169977
Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma
Abstract
Sixteen women with advanced epithelial ovarian carcinoma were treated with Aclacinomycin-A 40 mg/M2 given as a weekly infusion for four consecutive weeks followed by a two week rest period. All had failed prior chemotherapy. No responses were observed. Nausea and vomiting were the most frequent side effect. Myelosuppression was minimal. This dose and schedule of Aclacinomycin-A are not recommended for further trials in ovarian carcinoma.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical